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Abstract
Introduction: The presence, relevance and regulation of the Sodium Iodide Symporter (NIS) in human mammary tissue
remains poorly understood. This study aimed to quantify relative expression of NIS and putative regulators in human breast
tissue, with relationships observed further investigated in vitro.
Methods: Human breast tissue specimens (malignant n=75, normal n=15, fibroadenoma n=10) were analysed by RQ-PCR
targeting NIS, receptors for retinoic acid (RARa, RARb), oestrogen (ERa), thyroid hormones (THRa, THRb), and also
phosphoinositide-3-kinase (PI3K). Breast cancer cells were treated with Retinoic acid (ATRA), Estradiol and Thyroxine
individually and in combination followed by analysis of changes in NIS expression.
Results: The lowest levels of NIS were detected in normal tissue (Mean(SEM) 0.70(0.12) Log10 Relative Quantity (RQ)) with
significantly higher levels observed in fibroadenoma (1.69(0.21) Log10RQ, p,0.005) and malignant breast tissue (1.18(0.07)
Log10RQ, p,0.05). Significant positive correlations were observed between human NIS and ERa (r=0.22, p,0.05) and RARa
(r=0.29, p,0.005), with the strongest relationship observed between NIS and RARb (r=0.38, p,0.0001). An inverse
relationship between NIS and PI3K expression was also observed (r=20.21, p,0.05). In vitro, ATRA, Estradiol and Thyroxine
individually stimulated significant increases in NIS expression (range 6–16 fold), while ATRA and Thyroxine combined caused
the greatest increase (range 16–26 fold).
Conclusion: Although NIS expression is significantly higher in malignant compared to normal breast tissue, the highest level
was detected in fibroadenoma. The data presented supports a role for retinoic acid and estradiol in mammary NIS
regulation in vivo, and also highlights potential thyroidal regulation of mammary NIS mediated by thyroid hormones.
Citation: Ryan J, Curran CE, Hennessy E, Newell J, Morris JC, et al. (2011) The Sodium Iodide Symporter (NIS) and Potential Regulators in Normal, Benign and
Malignant Human Breast Tissue. PLoS ONE 6(1): e16023. doi:10.1371/journal.pone.0016023
Editor: Marian Ludgate, Cardiff University, United Kingdom
Received September 8, 2010; Accepted December 3, 2010; Published January 19, 2011
Copyright:  2011 Ryan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by funding from Cancer Research Ireland (www.cancer.ie/research) (J. Ryan), Health Research Board of Ireland (www.hrb.ie)
(R. M. Dwyer, J. Newell), and the National Breast Cancer Research Institute (NBCRI) (www.nbcri.ie). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: roisin.dwyer@nuigalway.ie
Introduction
The Sodium Iodide Symporter (NIS) is a transmembrane
glycoprotein found predominantly in thyroid follicular cells and
mediates the active transport of iodide. This supports production
of thyroid hormones Tri-iodothyronine (T3) and Thyroxine (T4),
and facilitates the use of radiolabelled iodide for imaging and
therapy of thyroid disease [1]. NIS is also expressed in
extrathyroidal tissue but to a much lower extent. It occurs in
salivary glands, small intestines, gastric mucosa, and of particular
interest in this study, mammary tissue [1]. NIS is known to be
naturally expressed in lactating mammary tissue to support iodide
concentration into breast milk for neonatal nutrition, but is not
normally detected at significant levels in nonlactating tissue [2].
Many studies have shown NIS expression in breast cancer,
combined with much lower prevalence in normal, or extratumoral
tissue [2,3,4,5,6,7]. However the majority of studies on NIS
expression in human tissue have been based on immunohisto-
chemistry (IHC) which is not a quantitative technique [2,4,5,6,7].
Studies investigating NIS gene expression in malignant breast
tissue provide a profile of expression which is limited due to small
cohort sizes [3,4]. Despite these limitations, it was a suggested that
NIS may represent a means of identifying malignant versus non
malignant tissue [2]. Functional NIS expression was shown in
human malignant mammary tissue with in vivo iodine transport
ability confirmed by scintigraphy [4,8]. Iodide uptake has also
been identified in soft tissue breast cancer metastases through
scintigraphy [9]. More recently, NIS protein was shown to be
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and so the characteristic of abnormal NIS protein expression in
breast tumours may be maintained in derivative metastases.
The earlier promise of the potential application of NIS as a
specific indicator of malignancy has been undermined by studies
which have shown NIS expression and iodide accumulation in
benign (fibroadenoma) tissue [3,6]. This is compounded by a study
highlighting functional NIS expression in a fibroadenoma which
was visible using a whole body gamma camera scan after
administration of cytotoxic radioiodide for treatment of thyroid
cancer [11].
The suitability of native functional NIS expression for treatment
of breast cancer using radiolabelled iodide is also in question with
the current consensus suggesting that native iodide uptake levels
would be insufficient to facilitate effective treatment. Approaches
have been investigated which could increase endogenous mam-
mary NIS expression by stimulation of putative regulators, but
while some data is promising [12,13], increased knowledge of
breast cancer and mammary NIS regulatory mechanisms is
required.
Regulation of NIS expression in the thyroid is well understood,
with Thyroid Stimulating Hormone (TSH) recognised as the
major positive regulator. Negative regulation is mediated through
inhibition of TSH by accumulation of T3 and T4 [1,14].
Thyroglobulin is also a potent suppressor of NIS mRNA
expression [15] and has been shown to suppress TSH-stimulated
NIS activity both in vitro and in vivo [16]. Negative feedback from
iodide accumulation, and cytokine mediated inhibition of NIS
expression also occur [1,14].
NIS regulation in mammary tissue has not yet been clearly
established. During lactation NIS expression was shown to be
optimal in the presence of oestrogen, prolactin and oxytocin [2].
In the case of breast cancer, a number of potential regulators of
NIS have been identified. Retinoic acid receptor a (RARa) has
been shown to increase NIS expression in MCF-7 cells in vitro
[17]. Induction of functional NIS expression in breast cancer
xenografts after treatment with Retinoic acid and Dexamethasone
has also been demonstrated [13]. An isoform of RAR, Retinoic
acid receptor b (RARb) has been shown to promote a greater
increase in NIS expression when similarly stimulated with RA in
MCF-7 cells [17]. The unliganded estrogen receptor alpha (ERa)
has also been shown to activate mammary NIS transcription in
oestrogen receptor positive breast cancer cell lines [18]. This is
supported by the presence of an oestrogen responsive element in
the NIS gene promoter [18]. Phosphoinositide-3-kinase (PI3K)
activation leads to increased NIS expression in MCF-7 cells and
has also been shown to diminish membrane localisation of the
protein in these cells [19,20]. Although no link has been
demonstrated in mammary tissue, the importance of thyroid
hormone receptors in thyroidal NIS expression [1], and their
differential expression in breast cancer warrants their investigation
as potential mammary NIS regulators [21,22,23]. Previous studies
of potential regulators of NIS expression in breast cancer, although
informative, have been performed using breast cancer cell lines
and animals models. Investigation of expression of potential
regulators and their pertinence to NIS in human breast tumour
tissue has not been performed.
The aim of this study was to determine the relative level of
expression of NIS, and a range of receptors for putative regulators
(ERa, RARa/b and THRa/b) in human breast tissue samples.
Further, based on relationships observed in normal, fibroadenoma
and malignant breast tissues, breast cancer cell lines were
stimulated with ligands for these receptors individually and in
combination, and their effect on NIS expression quantified.
Materials and Methods
Ethics Statement
For research involving tissue samples from human participants,
ethical approval was granted by the Clinical Research Ethics
Committee (University College Hospital, Galway). Written
informed consent was obtained from each patient and all clinical
investigation was conducted according to the principles expressed
in the Declaration of Helsinki.
Study Cohort
Breast tissue biopsies (n=100) were obtained at the University
College Hospital, Galway. The cohort consisted of 75 malignant
mammary tissue biopsies, 15 normal mammary tissue biopsies
harvested at reduction mammoplasty and 10 fibroadenoma
biopsies. Patient demographics for this study cohort are shown
in Table 1. Samples were snap frozen in liquid nitrogen
immediately after excision and stored at 280uC until processed.
Gene expression analysis
Biobanked tissue biopsies were homogenised briefly in 1 ml
TRIzolH Reagent (Invitrogen) using a Polytron PT 1600 E @
30,000 rpm. Total RNA was extracted from malignant (n=75),
normal (n=15) and fibroadenoma (n=10) mammary tissue using the
RNeasy Mini Kit (QIAGEN) as per manufacturer’s instructions.
Note: (1) TRIzolH Reagent was substituted for lysis buffer provided in
extraction kit. (2) An on-column DNase digestion step was performed
between RW1 washes. RNA was quantified using the Nandrop ND-
1000 Spectrophotometer (NanoDrop Technologies Inc, Wilmington,
DE, USA). 1 mg RNA was reverse transcribed using SuperScript III
reversetranscriptaseenzyme(Invitrogen,Carlsbad,CA,USA). cDNA
was analysed by real-time quantitative PCR (RQ-PCR) using the ABI
Prism 7000 (Applied Biosystems, Warrington, UK). TaqMan H Gene
Expression Assays were used in TaqMan H Universal Mastermix
(Applied Biosystems). Assays targeting 7 genes were as follows: NIS,
RARa,R A R b,E R a,P I 3 K ,T H R a and THRb. Expression data was
normalised to corresponding values for endogenous control assays for
Mitochondrial Ribosomal Protein L19 (MRPL19) and Peptidyl-Prolyl
Isomerase A (PPIA) [24]. The comparative DDCt method was used to
c a l c u l a t er e l a t i v eg e n ee x p r e s s i o na n de x p r e s s e da saL o g 10 Relative
Quantity [25]. Data was expressed relative to the lowest detectable
sample in the cohort analysis and to appropriate diluent controls in
the cell line stimulation study.
Immunohistochemistry
5 mm sections of snap frozen normal, fibroadenoma and
malignant breast biopsies from a subset of the same patient cohort
were cut and mounted on slides. These sections were probed using
a mouse anti-human NIS antibody [26], and the Discovery
TM
DABMap Kit on a Discovery
TM Ventana system. Slides were
washed in warm soapy water to remove oil, followed by rinsing in
ddH20. The slides were then treated sequentially as follows: 3 mins
in 75% alcohol, 3 mins in 95% alcohol, 3 mins in 100% alcohol,
and 2 serial immersions of 3 mins in Xylene. The slides were then
mounted in DPX mounting medium and analysed using an
Olympus BX60 microscope and analySIS Soft Imaging System.
Images were captured at 2006and 4006magnifications.
Cell Culture
T47D cells, characterised as estrogen and progesterone receptor
(ER/PR) positive and Her-2/neu (Her2) negative, were cultured
in RPMI 1640 medium. SK-Br-3 cells (ER/PR –ve, Her-2/neu
+ve) were cultured in McCoys-5a medium. All media were
supplemented with 10% foetal bovine serum (FBS), 100 IU/ml
Sodium Iodide Symporter and Breast Cancer
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Cells were incubated at 37uC and 5% CO2, with media change
three times per week and passage every seven days.
In vitro stimulation of NIS gene expression
In initial experiments, performed in triplicate, T47D and SK-
Br-3 cell lines were seeded at a density of 2.4610
4/cm
2, and
incubated in the presence of b-Estradiol (E2)(1 nM, 10 nM,
50 nM), all trans Retinoic Acid (ATRA, 0.1 mM,1 mM,5 mM) or
L- Thyroxine (T4)(0.1 mM, 0.5 mM, 1 mM) for 24 or 72 hrs. Media
and stimulants were replenished at 24 hr intervals, and control
cells were cultured in the appropriate diluent used for each
stimulant e.g. 0.1% NH4OH for T4 and 0.5% DMSO for ATRA.
Following establishment of the optimal time point (24 hrs) and
concentration (10 nM E2,1 mMA T R Aa n d0 . 1 mMT 4)t h e
experiment was repeated in triplicate using the optimal concentration
individuallyorincombination.Cellswereharvestedattheappropriate
time points by trypsinisation, centrifuged @ 1000 rpm for 4 mins and
the cell pellet stored @ 280uC. RNA was extracted and the
corresponding cDNA analysed using RQ-PCR targeting NIS and the
endogenous controls PPIA and MRPL19 as described. The data was
expressed relative to cells grown in appropriate diluent controls.
Statistical analysis
Continuous variables are summarised numerically by Mean
(SEM), and graphically using boxplots and scatterplots. A two sample
Student’s t test and a general linear model ANOVA were used to
compare mean responses as appropriate. Scatter plots with linear
regression and Lowess smoother lines were used to determine the
likely relationships between variables of a population. The degree of
relationship was assessed using Pearson correlation coefficients. The
corresponding 1-tailed p value was calculated using the r to p value
calculator available at http://faculty.vassar.edu/lowry/tabs.html.
Results
NIS expression in human breast tissue
Total RNA extracted from malignant (n=75), normal (n=15),
and fibroadenoma (n=10) breast tissue biopsies was analysed
using RQ-PCR targeting NIS, RARa, RARb,E R a, PI3K, THRa
and THRb. The resulting gene expression data was normalised to
endogenous controls MRPL19 and PPIA and expressed relative to
the lowest detectable sample for each target. Results were
expressed as Log10 Relative Quantity (RQ).
NIS was detectable in 98/100 samples analysed. Expression
levels were significantly higher in breast cancer (Mean (SEM) 1.18
(0.07) Log10 RQ, p,0.05) and fibroadenoma tissue (1.69 (0.21)
Log10 RQ, p,0.005) than normal tissue (0.70 (0.12) Log10 RQ,
Figure 1). The highest level of NIS expression overall was observed
in fibroadenoma tissue. When divided on the basis of epithelial
subtype, the highest level of NIS expression was observed in the
Her2 subgroup (1.43 (0.11) Log10 RQ, Figure 1). Data was also
subdivided on the basis of prognostic indicators such as disease
stage, tumour grade, menopausal status, estrogen, progesterone,
and Her-2/neu status, with no statistically significant relationship
observed between NIS and these clinical characteristics.
Immunohistochemical analysis of NIS protein in selected
human breast tissues
Tissue sections of selected snap frozen biopsies from the patient
cohort were prepared and examined for expression of NIS protein
using a mouse anti human monoclonal NIS antibody and
DABMap staining. Thyroid tissue, which was used as a positive
control, was strongly immunopositive for the protein (Figure 2a).
Antibody free controls for each sample were confirmed to be
negative, with an example of the fibroadenoma antibody free
control shown (Figure 2b, Note: 2006 magnification used for a
larger field of view). Strong membrane targeted NIS expression
was observed in fibroadenoma tissue (Figure 2c). Positive staining
was also observed in breast cancer tissues with an example shown
of each individual epithelial subtype; Luminal A (Figure 2d),
Luminal B (Figure 2e), Her2 (Figure 2f) and Basal (Figure 2g).
Expression of receptors for putative NIS regulators in
human breast tissue
Expression of both RARa and RARb were highest in
fibroadenoma tissue (Figure 3a). In the case of RARb, this was
Table 1. Patient demographics of study cohort.
Patient cohort details
Breast Cancer Fibroadenoma Normal
No. of Subjects 75 10 15
Premenopausal 24 9 12
Postmenopausal 51 1 3
Mean age (range) 57 (35–90) 36 (20–50) 48 (33–78)
Premenopausal 46 (35–59) 34 (20–49) 43 (33–48)
Postmenopausal 62 (41–90) 50 62 (50–78)
Histology Ductal Lobular Other
58 11 6
Epithelial Subtype Luminal A Luminal B HER2 Basal
31 17 13 14
Disease Stage Stage 1 Stage 2 Stage 3 Stage 4
17 35 15 8
Disease Grade Grade 0 Grade 1 Grade 2 Grade 3
432 3 4 5
doi:10.1371/journal.pone.0016023.t001
Sodium Iodide Symporter and Breast Cancer
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(p,0.001, p,0.005 respectively Figure 3a), which displayed
similar levels of RARb expression. In the case of RARa,
expression was also significantly higher in tumour compared to
normal tissue (p,0.005, Figure 3a), with no significant difference
between malignant and fibroadenoma tissue levels (Figure 3a).
Figure 1. NIS expression in normal, fibroadenoma (‘‘Fibro’’) and malignant breast tissue. Results have been normalised to the
endogenous controls PPIA and MRPL19 and expressed relative to the lowest detectable sample. Note: Results in breast cancer patients are also
stratified by epithelial subtype.
doi:10.1371/journal.pone.0016023.g001
Figure 2. Immunohistochemical detection of NIS protein expression in 5 mM sections of selected tissues from patient cohort. (a)
Thyroid tissue (positive control) (4006), (b) Antibody free Fibroadenoma (negative control) (2006), (c) Fibroadenoma (4006). Also shown are breast
cancer epithelial subtypes Luminal A (d), Luminal B (e), Her2 (f) and Basal (g) at 4006magnification.
doi:10.1371/journal.pone.0016023.g002
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lines, linear relationships were observed between NIS and both
retinoic acid receptors (Figure 3b, 3c). A Pearson Correlation
Coefficient of r=0.29 was observed between NIS and RARa
(p,0.005, Figure 3b), while a more robust relationship was
observed between NIS and RARb (r=0.38, p,0.0001, Figure 3c).
In the case of thyroid hormone receptors, expression of both
isoforms (a and b) was significantly lower in malignant compared
to normal tissue (p,0.001, p,0.005 respectively, Figure 3d).
Conversely, THRb was significantly higher in fibroadenoma tissue
compared to normal (p,0.0001). No significant relationship was
observed between NIS and THR a or b in the complete cohort.
ERa expression was higher in both fibroadenoma and malignant
breast tissue compared to normal (Figure 4a). A linear relationship
and significant correlation was observed between NIS and ERa
(r=0.22 p,0.05, Figure 4b). This was particularly strong within the
Her2 epithelial subtype (r=0.76 p,0.01, n=13). PI3K expression
was significantly lower in both fibroadenoma and malignant
compared to normal breast tissue (p,0.0005, p,0.0001 respec-
tively, Figure 4c) with a negative correlation observed between NIS
and PI3K (r=20.21 p,0.05, n=97, Figure 4d).
In vitro stimulation of NIS gene expression
Following on from the gene expression study in the breast tissue
samples, some of the observations were further investigated in an
in vitro setting through stimulation of breast cancer cell lines with
ligands targeting putative regulators of NIS. Breast cancer cell
lines, grown in the presence of varying concentrations of estradiol
(E2), all trans retinoic acid (ATRA) and thyroxine (T4) for 24 or
72 hrs, were harvested and changes in NIS gene expression
analysed by RQ-PCR. Expression data is normalised to
endogenous controls PPIA and MRPL19 and expressed relative
to cells grown in appropriate diluent controls.
In the case of the T47D cell line NIS expression was increased
in the presence of all 3 ligands following both 24 and 72 hr
incubation (Figure 5a): E2 (range 3–6 fold), ATRA (range 3–10
fold), T4 (range 4–7 fold). The greatest, most consistent increases
seen in T47D cells were with 10 nM E2 at 24 hrs (Mean (SEM)
fold change 6 (2) fold), 1 mM ATRA at 24 hrs (6 (1) fold), and
0.1 mMT 4 at 72 hrs (6 (3) fold).
A similar pattern was observed for the SK-Br-3 cell line
(Figure 5b). Stimulation with E2 resulted in a 3–7 fold increase in
NIS expression, ATRA stimulated a 6–16 fold increase, while T4
resulted in a 3–8 fold increase. The greatest most consistent
change in NIS expression was observed in the presence of 10 nM
E2 at 24 hrs (Mean (SEM) fold change 5 (1) fold), 1 mM ATRA at
24 hrs (9 (2) fold), and 0.1 mMT 4 at 24 hrs (7 (1) fold).
As shown in Figure 5a and 5b, incubation in the presence of any
of the stimulants for 72 hrs did not confer a significant advantage
and so subsequent incubations were performed for 24 hrs.
Optimal concentrations of ligands were selected based on the
largest most consistent increase in NIS expression observed in
Figure 3. RARa and RARb expression in breast tissue samples, and their relationship with NIS. (a) RARa and RARb expression in normal,
malignant and fibroadenoma breast tissue. Results have been normalised to the endogenous controls PPIA and MRPL19 and expressed relative to the
lowest detectable sample. Correlations of NIS gene expression with RARa (b) and RARb (c) with r and p values shown (* one outlier removed). (d)
THRa and THRb expression in normal, malignant and fibroadenoma breast tissue.
doi:10.1371/journal.pone.0016023.g003
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The experiment was repeated in triplicate treating cells with
ligands for 24 hrs both individually and in combination.
Increased NIS expression was observed in the presence of all 3
ligands when used individually (Figure 5c). In both the T47D and
Sk-Br-3 cell lines, the combination of ATRA and T4 created the
greatest increase in NIS expression observed (Mean (SEM): 26 (1)
and 16 (1) fold increase respectively, Figure 5c). Addition of E2 to
this combination did not have a significant impact on NIS gene
expression. The change in expression was greater than the sum of
increases when the cells were cultured in the presence of each
factor individually. Based on this, gene expression data from the
patient cohort was re-examined to determine whether there was
any relationship between retinoic acid receptors and thyroid
hormone receptors in human tissue samples. Further investigation
of the expression of these receptors in human tissues revealed a
linear relationship and significant positive correlation between
RARb and THRb across all samples (r=0.49, p,0.0001, n=100,
Figure 5d).
Discussion
The presence, function and regulation of the sodium iodide
symporter have been well established in thyroid tissue. This has led
to a better understanding of thyroid diseases and effective imaging
and therapy using radioactive iodide [27]. NIS is also known to
play a role in the breast and is present in a functional capacity in
lactating breast tissue [2]. Expression of the NIS gene and
functional protein has been demonstrated in fibroadenoma and
malignant breast tissue but typically not in normal breast tissue
[3,6,11]. Understanding the nature of mammary NIS expression
would not only be useful in breast cancer research but may
potentially benefit understanding of other extrathyroidal malig-
nant tissues expressing NIS, including ovary, lung, colon, and
endometrium [6]. Investigation of mammary NIS regulation will
support elucidation of the nature of NIS dysregulation in
malignant compared to normal tissue.
To date, quantitative analysis of NIS expression in a large
cohort of human breast tissue samples has not been performed. In
the current study, expression of NIS and receptors for putative
regulators was quantified by RQ-PCR, in 100 human breast tissue
samples, and relationships observed further investigated in vitro.
NIS expression was observed to be significantly higher in
malignant compared to normal breast tissue, with the highest
levels detected in fibroadenoma. This data agrees with previous
smaller studies showing increased NIS expression in malignant
tissue [3,4], and also more surprisingly in fibroadenoma compared
to malignant tissue [3]. Immunohistochemical analysis of a subset
of tissues from the same cohort also confirmed the presence of NIS
protein in selected malignant and benign breast tissues. Thus it is
abundantly clear that native NIS expression in breast cancer
cannot serve as a useful marker of malignancy.
NIS expression levels across all tissue samples examined were
shown to correlate to that of receptors for potential regulators
Figure 4. ERa and PI3K expression in breast tissue samples and their relationship with NIS. Expression of ERa (a) and PI3K (b) in normal,
malignant and fibroadenoma breast tissue. Results have been normalised to the endogenous controls PPIA and MRPL19 and expressed relative to the
lowest detectable sample. Correlation of NIS gene expression with ERa (c) and PI3K (d) with r and p values shown.
doi:10.1371/journal.pone.0016023.g004
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models [2,13,17,18].
Expression of NIS, RARa and ERa were significantly higher in
malignant compared to normal breast tissue, with a significant
positive correlation observed between NIS and RARa (r=0.29
p,0.005) and ERa (r=0.22 p,0.05). This supports previous in
vitro and in vivo studies showing ATRA mediated stimulation of
NIS expression [13,17]. Alotaibi and colleagues recently reported
a potent enhancer of NIS expression located in the first intron of
the NIS gene that mediates direct regulation by trans retinoic acid-
stimulated nuclear receptors which include RARa [28]. The same
group also reported an estrogen-responsive element in the
promoter region of NIS gene that specifically binds ERa and
mediates ERa-dependent activation of transcription [18].
Previous studies using breast cancer cell lines have suggested
that selective stimulation of RARb increases NIS expression more
efficiently than that of RARa [17]. The data presented here on
expression of RARb and NIS in human breast tissue samples
supports this, with the largest, most significant correlation detected
between expression of these two genes (r=0.38 p,0.0001).
PI3K was previously reported to mediate increased NIS gene
expression in MCF-7 breast cancer cells [19,29]. However, in the
current study an inverse relationship and significant negative
correlation between NIS and PI3K was observed (r=20.21
p,0.05). This negative correlation suggests that inhibition of PI3K
may increase mammary NIS expression. Stratification of the
patient cohort based on tumour epithelial subtype revealed that
while the overall negative correlation between NIS and PI3K was
significant, within the Luminal A subtype which MCF-7 cells
represent, there was a positive relationship (albeit not significant),
between the two genes. This may explain the conflicting data
observed and highlights the importance of using multiple cell types
when attempting to represent this heterogeneous disease.
It is interesting to note that the 3 genes in this study found to be
differentially expressed in fibroadenoma and malignant tissue
(NIS, RARb and THRb), have all been suggested to have tumour
suppressor roles. Gol Choe et al, have proposed NIS transgene
inhibition of oncogenic RAS-mediated signalling [30]. RARb2
overexpression has been shown to result in decreased metastatic
potential of MDA-MB-435 in vivo [31]. Reports of decreased
THRb expression in breast tumours relative to normal tissue
[21,23,32], which was also observed in the current study, and
THRb1 suppression of tumour invasiveness and metastasis [21]
suggest an anti-tumour role for THRb. Based on these studies, and
the data presented here, it may be postulated that in rapidly
proliferating mammary epithelial cells, loss of expression of these
genes may be involved in tumour pathogenesis.
The current study revealed upregulation of NIS expression
through stimulation of both the retinoic acid and estrogen
receptors with relevant ligands (ATRA and E2) in breast cancer
epithelial cell lines. Data generated from the ER positive T47D
cell line supports previous studies which demonstrated retinoic
acid [13,17] and estradiol stimulation of NIS expression [2,18].
However, it is interesting that stimulation of NIS gene expression
Figure 5. Effect of b-estradiol (E2), all trans Retinoic Acid (ATRA) and L-thyroxine (T4) on NIS expression in breast cancer cell lines.
Effect of indivdual stimulants on NIS expression in (a) T47D and (b) SkBr3 cell lines. Results have been normalised to the endogenous controls PPIA
and MRPL19 and expressed relative to diluent controls, with the baseline representing 2
2(ddCt diluent control).( c) NIS expression in T47D and SkBr3 cells
following 24 hr stimulation with optimal concentrations of ligands alone and in combination. (d) Correlation of RARb with THRb gene expression
within patient cohort with r and p values shown.
doi:10.1371/journal.pone.0016023.g005
Sodium Iodide Symporter and Breast Cancer
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which are characterised as ER negative by IHC. This contradicts
the hypothesis that RA-responsive NIS expression is confined to
estrogen receptor-alpha (ERa) positive cells [18], and suggests that
in the absence of substantial ER expression some other mechanism
of stimulation is at play.
While no direct relationship between expression of NIS and
THRa or THRb was observed, in vitro studies revealed significant
stimulation of NIS expression in cell lines exposed to thyroid
hormone. Dimerization between retinoic acid receptors and
thyroid hormone receptors is known to occur [33,34]. Hetero-
dimerisation between retinoid-X-receptor and pregnane-X-recep-
tor has been identified as the basis for carbazmazepine stimulation
of NIS expression in MCF-7 cells [12]. Indeed in the current
study, the greatest induction of NIS expression was seen in the
presence of ATRA and T4 combined, where a synergistic increase
greater than the sum of that seen with the individual factors alone
was observed. Further analysis of this relationship in patient
samples revealed a significant positive correlation between RARb
and THRb (r=0.49 p,0.0001). The positive effect on mammary
NIS expression observed in vitro is in contrast to the inhibitive role
T4 plays in thyroidal NIS regulation.
Conclusion
Although NIS expression is significantly higher in malignant
compared to normal breast tissue, the highest level was detected in
fibroadenoma, indicating that NIS expression in breast cancer
cannot serve as a useful marker of malignancy. However this does
not preclude the use of native NIS expression as a tool for imaging
or therapy of the disease. Indeed, a pilot imaging study is currently
underway to determine radioiodine accumulation and dosimetry
in breast cancers using
124I PET/CT (Clinicaltrials.gov). In the
context of other non-thyroidal cancers, a previous Phase I trial
demonstrated safety and feasibility of virus mediated delivery of
NIS for imaging prostate cancer [35]. Two further clinical trials
are also currently underway utilising NIS as both a reporter for
virus tracking in patients with multiple myeloma, and for gene
therapy of prostate cancer in conjunction with radioiodine
(Clinicaltrials.gov).
The data presented support a role for retinoic acid and estradiol
in mammary NIS regulation in vivo, and also highlight potential
thyroidal regulation of mammary NIS mediated by thyroid
hormones. Increased understanding of extra-thyroidal expression
and regulation of NIS will support further development of the
imaging and therapeutic potential of NIS in the clinical setting.
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